Paget's disease of the breast differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 26: Line 26:
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Benign or Malignant
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Benign or Malignant
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! colspan="9" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations
! colspan="8" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations
! colspan="2" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
! colspan="2" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
| rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold Standard
| rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold Standard
| rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Associated factors'''
| rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Associated factors'''
|-
|-
! colspan="7" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms
! colspan="6" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms
! colspan="2" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination
! colspan="2" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination
|-
|-
Line 40: Line 40:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Nipple Discharge
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Nipple Discharge
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Erythema
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Erythema
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Single/
Multiple
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Involved areas
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Involved areas
Line 56: Line 54:
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
Line 86: Line 83:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 127: Line 123:
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |May be multiple after 1-2 days of exposure
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | Surrounding the area in contact with the offending agent  
| align="center" style="background:#F5F5F5;" | Surrounding the area in contact with the offending agent  
Line 154: Line 149:
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 180: Line 174:
|-
|-
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Melanoma|Malignant melanoma]]
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Melanoma|Malignant melanoma]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 200: Line 193:
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Erythematous
* Skin colored
* Patch
* Plaque
* scaly
* variable size
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Fair-skinned individuals: sun-exposed areas
* In black individuals: legs, anus, and areas of chronic inflammation
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 209: Line 212:
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Keratinocytic dysplasia of the epidermis
* No infiltration into dermis
 
* Pleomorphic keratinocytes
* Hyperchromatic nuclei
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 217: Line 224:
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Erythematous
* Superficial scaly patch
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Sun-exposed areas
* Head (cheek and nose)
* Trunk
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Superficial fine telangiectasia
* Shiny white to red, translucent or opaque structureless areas
* Multiple small erosions
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Large, hyperchromatic, oval nuclei
* Minimal cytoplasm
* Small basaloid nodules
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
|-
|-
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Basal cell carcinoma|Pagetoid basal cell carcinoma]]
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Basal cell carcinoma|Pagetoid basal cell carcinoma]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 248: Line 264:
|-
|-
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Intraductal papilloma|Benign intraductal papilloma]]
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Intraductal papilloma|Benign intraductal papilloma]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 265: Line 280:
|-
|-
! style="background: #DCDCDC; padding: 5px; text-align: center;" |Pagetoid dyskeratosis
! style="background: #DCDCDC; padding: 5px; text-align: center;" |Pagetoid dyskeratosis
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 285: Line 299:
| align="center" style="background:#F5F5F5;" |* Common among [[perimenopausal]]<nowiki/>women
| align="center" style="background:#F5F5F5;" |* Common among [[perimenopausal]]<nowiki/>women
* Usually resolve spontaneously
* Usually resolve spontaneously
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 302: Line 315:
|-
|-
! style="background: #DCDCDC; padding: 5px; text-align: center;" |Nipple duct adenoma
! style="background: #DCDCDC; padding: 5px; text-align: center;" |Nipple duct adenoma
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 319: Line 331:
|-
|-
! style="background: #DCDCDC; padding: 5px; text-align: center;" |Benign Toker cell  hyperplasia
! style="background: #DCDCDC; padding: 5px; text-align: center;" |Benign Toker cell  hyperplasia
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 337: Line 348:
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Breast abscess]]
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Breast abscess]]
| align="center" style="background:#F5F5F5;" |Benign
| align="center" style="background:#F5F5F5;" |Benign
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 357: Line 367:
|-
|-
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Mondors disease]]
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Mondors disease]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 377: Line 386:
* [[Benign]]
* [[Benign]]
* No increased risk of [[malignancy]]
* No increased risk of [[malignancy]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 401: Line 409:
|-
|-
! style="background: #DCDCDC; padding: 5px; text-align: center;" |Inflammatory Breast Cancer
! style="background: #DCDCDC; padding: 5px; text-align: center;" |Inflammatory Breast Cancer
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |

Revision as of 17:03, 21 February 2019

Paget's disease of the breast Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Paget's disease of the breast from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Biopsy

Ultrasonography

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Paget's disease of the breast differential diagnosis On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Paget's disease of the breast differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Paget's disease of the breast differential diagnosis

CDC on Paget's disease of the breast differential diagnosis

Paget's disease of the breast differential diagnosis in the news

Blogs on Paget's disease of the breast differential diagnosis

Directions to Hospitals Treating Paget's disease of the breast

Risk calculators and risk factors for Paget's disease of the breast differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Suveenkrishna Pothuru, M.B,B.S. [2]

Overview

Paget's disease of the breast must be differentiated from atopic dermatitis, eczema, psoriasis, malignant melanoma, Bowen's disease, basal cell carcinoma, and pagetoid dyskeratosis.[1][2]

Differential Diagnosis

Paget’s disease of the breast must be differentiated from other benign and malignant processes of nipple-areola complex such as:[1][2]

Category Diseases Benign or Malignant Etiology Clinical manifestations Para-clinical findings Gold Standard Associated factors
Symptoms Physical examination
Lab Findings Histopathology
Rash Nipple Discharge Erythema Involved areas Mastalgia Breast Exam Other Serum IgE
Eczema Scalp, face, trunk, postauricular, diaper area and axilla + +
Nl Risk factors include

Generalized seborrheic erythroderma in immunodeficient patients

Skin disorders Atopic dermatitis Benign
  • Epidermal barrier dysfunction
  • Immune dysregulation
+
  • Young children -Scalp, cheeks amd extensor surface
  • Adolescents -flexural areas and buttock-thigh creases
  • Adults - facial involvement and skin flexures
Allergic contact dermatitis[3] Benign Erythematous well-demarcated papules + Surrounding the area in contact with the offending agent + Nl
Psoriasis Benign Well-circumscribed, pink papules and symmetrically distributed cutaneous plaques with silvery scales + +
  • Scalp
  • Trunk
  • Gluteal cleft
  • Extensor surface of elbows and knees
+ Nl Risk factors include
Malignant melanoma
Bowen’s disease
  • Erythematous
  • Skin colored
  • Patch
  • Plaque
  • scaly
  • variable size
  • Fair-skinned individuals: sun-exposed areas
  • In black individuals: legs, anus, and areas of chronic inflammation
  • Keratinocytic dysplasia of the epidermis
  • No infiltration into dermis
  • Pleomorphic keratinocytes
  • Hyperchromatic nuclei
Superficial basal cell carcinoma
  • Erythematous
  • Superficial scaly patch
  • Sun-exposed areas
  • Head (cheek and nose)
  • Trunk
  • Superficial fine telangiectasia
  • Shiny white to red, translucent or opaque structureless areas
  • Multiple small erosions
  • Large, hyperchromatic, oval nuclei
  • Minimal cytoplasm
  • Small basaloid nodules
Pagetoid basal cell carcinoma
Benign intraductal papilloma
Pagetoid dyskeratosis
Lactiferous duct ectasia Benign * Common among perimenopausalwomen
  • Usually resolve spontaneously
* Distention of subareolar ducts Ultrasound:
  • Dilated milk ducts
  • Fluid-filled ducts
Nipple duct adenoma
Benign Toker cell hyperplasia
Breast abscess Benign +

Ultrasound:

  • Fluid collection
Mondors disease
Mastitis + ±

Breast parenchymainflammation:

Ultrasound:

  • Ill-defined area with hyperechogenicity with inflamed fat lobules
  • Skin thickening
Inflammatory Breast Cancer

References

  1. 1.0 1.1 Gaspari, Eleonora; Ricci, Aurora; Liberto, Valeria; Scarano, Angela Lia; Fornari, Maria; Simonetti, Giovanni (2013). "An Unusual Case of Mammary Paget's Disease Diagnosed Using Dynamic Contrast-Enhanced MRI". Case Reports in Radiology. 2013: 1–5. doi:10.1155/2013/206235. ISSN 2090-6862.
  2. 2.0 2.1 Lopes Filho, Lauro Lourival; Lopes, Ione Maria Ribeiro Soares; Lopes, Lauro Rodolpho Soares; Enokihara, Milvia M. S. S.; Michalany, Alexandre Osores; Matsunaga, Nobuo (2015). "Mammary and extramammary Paget's disease". Anais Brasileiros de Dermatologia. 90 (2): 225–231. doi:10.1590/abd1806-4841.20153189. ISSN 1806-4841.
  3. Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF (2009). "Allergic and irritant contact dermatitis". Eur J Dermatol. 19 (4): 325–32. doi:10.1684/ejd.2009.0686. PMID 19447733.